The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: A systematic review and meta-analysis

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Guessous, Idris ^a   Periard, Daniel ^a   Lorenzetti, Diane ^b,c   Cornuz, Jacques ^a   Ghali, William A ^b,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF CALGARY   (Canada)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXYCYCLINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAVASTATIN; PROPRANOLOL; ROXITHROMYCIN; SIMVASTATIN;

ABDOMINAL AORTA ANEURYSM; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; EMBASE; HUMAN; INFORMATION PROCESSING; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; PATHOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AORTIC ANEURYSM, ABDOMINAL; COHORT STUDIES; DOXYCYCLINE; HUMANS; ROXITHROMYCIN;

EID: 46749133530     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001895     Document Type: Review

References (53)

1. Fleming C, Whitelock EP, Beil TL, Lederle FA (2005) Screenning for abdominal aortic aneurysm: a best-evidence systematic review for the US Preventive Sevices task Force. Ann Intern Med 142: 203-11.
2. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, et al. (2002) Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 346: 1437-44.
3. The UK Small Aneurysm trial Participants (1998) Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysm. Lancet 352: 1649-1655.
4. Guessous I, Cornuz J (2006) Abdominal aortic aneurysm screening: 2006 recommendations. Expert Rev Pharmacoeconomics Outcomes Res 6: 555-561.
5. Scott RA, Thompson SG (2005) Screening, surgical repair, and the management of abdominal aortic aneurisms. J Med Screen 12: 57-58.
6. Wilson KA, Woodburn KR, Ruckley CV, Fowkes FG (1997) Expansion rates of abdominal aortic aneurysm: current limitations in evaluation. Eur J Vasc Endovasc Surg 13: 521-526.
7. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MY, et al. (2001) Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung and Blood Instituie. J Vasc Surg 34: 730-738.
8. Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM (1996) Indomethacin prevents elastase-induced abdominal aortic aneurysm in the rat. J Surg Res 63: 305-309.
9. Petrinec D, Liao S, Holmers DR, Reilly JM, Parks WC, et al. (1996) Doxycycline inhibition of aneurismal degenration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23: 336-346.
10. Petrinec D, Holmes DR, Liao S, Golub LM, Thompson RW (1996) Suppression of experimental aneurismal degeneration with chemically modified tetracycline derivates. Ann N Y Acad Sci 800: 263-265.
11. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, et al. (2001) Suppression of experimental abdominal aortic aneurysm in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 33: 1057-1064.
12. Thompson RW, Baxter BT (1999) MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 878: 159-178.
13. Lefebvre C, Clarke M (2001) Identifying randomized trials. In: Egger M, Davey Smith G, Altman DC, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London, United Kingdom: BMJ Publishing Group. pp 69-86.
14. Decks JL, Altman DG, Bradburn MJ (2001) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care. Meta-analysis in Context. London, United Kingdom: BMJ Publishing Group. pp 285-312.
15. Jadad AR, Moore RA. Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
16. Thomson S, Sharp SJ (1999) Explaining heterogeneity in meta-analysisis. A comparison of methods. Stat Med 18: 2693-2708.
17. Sterne JA, Gradgurn MJ, Egger M (2001) Meta-analysis in Stata™ In:Egger M, Smith GD, Altman DG, eds. Systematic Reviews in Health Care. Meta-Analysis in Context. London, United Kingdom: BMJ Publisbing Group. pp 347-369.
18. Dear K, Begg CB (1992) An approach for assessing publication bias prior to performing a meta-analyisis. Stat Sci 7: 237-245.
19. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
20. Englund R, Hudson P, Hanel K, Stanton A (1998) Expansion rates of small abdominal aortic aneurysms. Aust N Z J Surg 68: 21-4.
21. Lindholt JS, Henneberg EW, Juul S, Fasting H (1999) Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 18: 52-7.
22. Propranolol Aneurysm Trial Investigators (2002) Propranolol for small abdominal aortic aneurysms: Results of a randomized trial. J Vasc Surg 35: 72-79.
23. Wilmink AB, Vardulaki KA, Hubbard CS, Day NE, Ashton HA, et al. (2002) Are antihypertensive drugs associated with abdominal aortic aneurysms? J Vasc Surg 36: 751-7.
24. Lindholt JS, Heegaard NH, Vammen S, Fasting H, Henneberg EW, et al. (2001) Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion or abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 21: 51-6.
25. Gadowski GR, Pilcher DB, Ricci MA (1994) Abdominal aortic aneurysm expansion rate: effect of size and beta-adrenergic blockade. J Vasc Surg 19: 727-31.
26. Leach SD, Toole AL, Stern H, DeNatale RW, Tilson MD (1988) Effect of beta-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg 123: 606-9.
27. Biancari F, Mosorin M, Anttila V, Satta J, Juvonen J, et al. (2002) Ten-year outcome of patients with very small abdominal aortic aneurysm. Am J Surg 183: 53-5.
28. Mosorin M, Juvonep J, Biancari F, Satta J, Surcel HM, et. al. (2001) Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized double-blind, placebo-controlled pilot study. J Vasc Surg 34: 606-10.
29. Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW (2001) Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 88: 1066-72.
30. Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, et al. (2006) Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32: 21-6.
31. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S (2006) Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97: 279-80.
32. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, et al. (1999) Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 100: 48-54.
33. Wilmink AB, Hubbard CS, Day NE, Quick CR (2000) Effect of propanolol on the expansion of abdominal aortic aneurysms: a rundomised study Br J Surg (Abstract) 87: 499.
34. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT, UK Small Aneurysm Trial Participants (2004) Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 110: 16-21.
35. Holmes DR, Wester W, Thompson RW, Reilly JM (1997) Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 25: 810-815.
36. Fletcher RH, Fletcher SW, Wagner EH (1996) Clinical epidemiology: the essentials. 3rd ed. Philadelphia: Lippincott Williams & Wilkins.
37. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, et al. (2001) Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 34: 730-8.
38. Bergoeing MP, Thompson RW, Curci JA (2006) Pharmacological targets in the treatment of abdominal aortic aneurysms. Expert Opin Ther Targets 10: 547-59.
39. Grange JJ, Davis V, Baxter BT (1997) Pathogenesis of abdominal aortic aneurysm: an update and look toward the future. Cardiovasc Surg 5: 256-65.
40. Shah PK (1997) Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 96: 2115-7.
41. Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K, et al. (1997) Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 25: 499-505.
42. Halme S, Juvonen T, Laurila A, Juvonen J, Mosorin M, et al. (1999) Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest 29: 546-52.
43. McMillan WD, Pearce WH (1999) Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 29: 122-7.
44. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, et al. (1998) HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18: 1671-8.
45. Nagashima H, Aoka Y, Sakomura Y, Sakuta A, Aomi S, et al. (2002) A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 36: 158-63.
46. Luan Z, Chase AJ, Newby AC (2003) Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Bio 23: 769-75.
47. Wilson WR, Evans J, Bell PR, Thompson MM (2005) HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 30: 259-62.
48. Thompson S (1994) Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309: 1351-1355.
49. Cronenwett JL (1996) Variables that affect the expansion rate and rupture of abdominal aortic aneurysms. Ann N Y Acad Sci 800: 56-67.
50. Limet R, Sakalihassan N, Albert A (1991) Determination or the expansion rate and incidence of rupture of abdominal aortic aneurysms. J Vasc Surg 14: 540-8.
51. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, et al. (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation 113: 463-654.
52. Kramer BS, Wilentz J, Alexander D, Burklow J, Friedman LM, et al. (2006) Getting it right: being smarter about clinical trials. PLoS Med 3(6): e144.
53. Berger VW (2004) Does the Prentice criterion validate surrogate endpoints? Stat Med 23: 1571-8.